Self-management behavior auxiliary system for pregnancy and epilepsy patients

Through the self-management behavior assistance system integrating detection unit and processing unit, the real-time multi-dimensional monitoring problem of pregnant epilepsy patients is solved, and the epilepsy management index during pregnancy is calculated, personalized risk assessment and immediate feedback are achieved, and the treatment effect and safety of pregnant epilepsy patients is improved.

CN120260900APending Publication Date: 2025-07-04XUANWU HOSPITAL OF CAPITAL UNIV OF MEDICAL SCI
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202510230521.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-02-28
Publication Date
2025-07-04

AI Technical Summary

Technical Problem

The existing technology is difficult to achieve real-time and personalized monitoring of pregnant patients with epilepsy, especially at home, where it is impossible to comprehensively evaluate multiple factors such as blood drug concentration, liver enzyme activity and blood sugar levels, resulting in untimely adjustment of treatment plans and increasing the safety risks of maternal and infants.

Method used

A self-management behavioral assistance system was designed, integrating multiple detection units to obtain physiological parameters, including blood drug concentration, liver enzyme activity and blood glucose levels, calculating the epilepsy management index (PEMI) during pregnancy through the processing unit, and monitoring the epilepsy risk in real time based on dynamic threshold analysis, providing visual feedback.

Benefits of technology

Multi-dimensional dynamic monitoring of pregnant patients with epilepsy has been achieved, treatment compliance and quality of life have been improved, epilepsy risks have been reduced, and mother-child safety has been ensured.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120260900A_ABST
    Figure CN120260900A_ABST
Patent Text Reader

Abstract

The invention relates to a self-management behavior auxiliary system for gestation and epilepsy patients, and belongs to the technical field of medical monitoring and diagnosis. The auxiliary system comprises a detection unit used for obtaining physiological parameters, related to pregnancy combined epilepsy, of a patient; the processing unit is used for analyzing and processing the data obtained by the detection unit so as to evaluate the health trend of the patient, and the physiological parameters obtained by the detection unit comprise the blood concentration, the liver enzyme activity and the blood sugar level. The processing unit can calculate and obtain a gestational epilepsy management index used for representing the health trend of the patient based on the physiological parameters so as to judge the epilepsy risk condition of the patient in the current gestational period.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medical monitoring and diagnosis, and particularly to a self-management behavior assistance system for pregnant women with epilepsy. Background Art

[0002] Pregnancy with epilepsy refers to the situation where a woman has epilepsy during pregnancy, which is a high-risk pregnancy state that requires special attention. Epilepsy is a chronic neurological disease characterized by recurrent seizures caused by abnormal electrical discharges of brain neurons. Seizures during pregnancy may pose potential risks to both the pregnant woman and the fetus. Therefore, pregnant women with epilepsy need to receive individualized multidisciplinary management to ensure the safety of the mother and baby.

[0003] Pregnancy with epilepsy poses multiple challenges to the health of the mother and baby. It not only increases the health risks of the pregnant woman but also poses a potential threat to the normal development of the fetus. During pregnancy, due to factors such as hormonal fluctuations, changes in drug metabolism, and lack of sleep, the seizure frequency may increase significantly. This not only affects the quality of life of the pregnant woman but also increases the risk of serious pregnancy complications such as miscarriage, premature birth, and placental abruption. In addition, the use of antiepileptic drugs (AEDs) helps control seizures but may also cause a series of side effects in the mother, such as liver and kidney function damage, reduced bone density, and cognitive dysfunction. Especially at high doses, certain AEDs are more likely to cause these adverse reactions. For the fetus, some antiepileptic drugs such as valproic acid have been proven to be associated with an increased incidence of congenital diseases such as fetal neural tube defects, cardiovascular malformations, and cleft lip and palate. During a grand mal seizure, the mother may experience loss of consciousness or apnea, directly threatening the safety of the fetus, which may lead to intrauterine hypoxia and further affect its growth and development.

[0004] During pregnancy, a series of significant physiological changes occur in a woman's body, including changes in hormonal levels, hepatic enzyme activity, and renal function. These changes have an important impact on the metabolism of antiepileptic drugs: increased hepatic enzyme activity leads to accelerated drug metabolism, increased glomerular filtration rate reduces the retention time of drugs in the body, and expanded blood volume dilutes the drug concentration in the blood, further reducing the effectiveness of the drugs. Therefore, it is necessary to flexibly adjust the drug dosage according to the results of blood drug concentration monitoring to ensure the therapeutic effect and reduce side effects. Regular monitoring of the blood drug concentration of antiepileptic drugs is a key link in the management of pregnant women with epilepsy, but traditional medical monitoring methods are difficult to meet the real-time and personalized needs, especially when at home, lacking sufficient flexibility and response speed.

[0005] Current research has shown that there is a high correlation between dried blood spots (DBS) and venous plasma concentrations, especially for lamotrigine and levetiracetam. Therefore, the DBS method can be used as a feasible alternative, especially in the case of home self-sampling (see: Besten-Bertholee, D., Wegner, I., Touw, D., & Ter Horst, P. Analytical and clinical validation of an LC-MS / MS method for carbamazepine, lamotrigine and levetiracetamin dried blood spots. European Journal of Hospital Pharmacy. 2024, 31(5): 450-454. and Linder, C., Neideman, M., Wide, K., Von Euler, M., Gustafsson, L., & Pohanka, A. Dried blood spot self-sampling by guardians of children with epilepsy is feasible: comparison with plasma for multiple antiepileptic drugs. Therapeutic Drug Monitoring. 2019, 41(4): 509-518.). However, the following problems still exist in the existing technology:

[0006] Insufficient monitoring frequency: Relying solely on going to medical institutions (such as hospitals) for blood drug concentration detection once every few weeks or even once a month makes it difficult to ensure the safety of pregnant women and fetuses in real time and comprehensively, and is not conducive to quickly adjusting the treatment plan;

[0007] Insufficient consideration of individual differences: The physiological parameter changes of different patients vary greatly, and fixed-cycle monitoring is difficult to meet the individualized treatment needs;

[0008] Lack of comprehensive evaluation: Existing monitoring systems often focus only on the changes in a single indicator and fail to conduct a comprehensive evaluation by combining multiple factors such as blood drug concentration, liver metabolism function, and blood glucose level;

[0009] Difficulty in patient self-management: Current methods rely on professional equipment and technical personnel in hospitals, and it is difficult for patients to complete effective self-management and monitoring at home, increasing the risks caused by improper drug doses and other situations.

[0010] The existence of these problems urgently requires a new solution to improve the management efficiency of patients with epilepsy during pregnancy and ensure the safety of the mother and baby.

[0011] In addition, on the one hand, there are differences in the understanding of those skilled in the art; on the other hand, when the applicant made this invention, a large number of literatures and patents were studied, but due to space limitations, all details and contents were not listed in detail. However, this does not mean that this invention does not possess the features of these prior arts. On the contrary, this invention already possesses all the features of the prior arts, and the applicant reserves the right to add relevant prior arts in the background art. Summary of the Invention

[0012] Aiming at the deficiencies of the prior art, the present invention provides a self - management behavior assistance system for patients with epilepsy during pregnancy to solve at least part of the above - mentioned technical problems.

[0013] The present invention discloses a self - management behavior assistance system for patients with epilepsy during pregnancy, which includes: a detection unit for obtaining physiological parameters of the patient related to epilepsy during pregnancy; a processing unit for analyzing and processing the data obtained by the detection unit to evaluate the health trend of the patient. The physiological parameters obtained by the detection unit include blood drug concentration, liver enzyme activity, and blood glucose level, so that the processing unit can calculate a pregnancy epilepsy management index for characterizing the health trend of the patient based on the above physiological parameters, and analyze the change trend of the pregnancy epilepsy management index based on a dynamically adjusted threshold to judge the epilepsy risk situation of the patient during the current pregnancy.

[0014] When faced with the problem of drug management for pregnant women with epilepsy, the inventors of the present invention first noticed that the complexity of the monitoring system for such patients stems from the interaction of diverse biomarkers, and the resulting multi-dimensional monitoring requirements lead to an efficiency bottleneck in medical decision-making. The present invention reduces the dimension of the monitoring system. More importantly, it establishes a three-dimensional evaluation framework for drug exposure, metabolic capacity, and pregnancy physiological status, representing a significant technological breakthrough compared to traditional broad-spectrum monitoring models. Thus, the present invention provides a self-management behavior assistance system for pregnant women with epilepsy, the core of which is to integrate multiple detection units to obtain physiological parameters related to pregnant women with epilepsy, including blood drug concentration, liver enzyme activity, and blood glucose level. By analyzing and processing these data through a processing unit, a Pregnancy Epilepsy Management Index (PEMI) can be calculated to characterize the health trend of the patient. This method fundamentally solves the problem that traditional monitoring methods only focus on changes in a single indicator and realizes multi-dimensional data integration. Specifically, blood drug concentration reflects the effectiveness and safety of drug treatment; liver enzyme activity indicates changes in drug metabolism rate, which helps to adjust drug dosage; and monitoring of blood glucose level is crucial for preventing epileptic seizures caused by hypoglycemia. By comprehensively evaluating these parameters, PEMI can more accurately reflect the overall health status and potential risks of the patient, providing a scientific basis for clinical decision-making. In addition, by analyzing the change trend of PEMI based on dynamically adjusted thresholds, the system can monitor and warn of epileptic risks in real time at different pregnancy stages, greatly improving the patient's self-management and treatment compliance.

[0015] In addition, the Epilepsy Management Index (PEMI) proposed by the present invention successfully integrates discrete biomarker measurement values into a continuous risk trajectory prediction. Regarding the establishment of a quantitative evaluation system, this solution enables early identification of small parameter offsets of pregnant women with limited mobility in the home scenario through a simple analysis algorithm for PEMI time-series data in the home scenario. In particular, in recent years, microfluidic chips have been used for blood drug concentration monitoring, the DBS method can be used to evaluate liver enzyme activity and has a relatively high correlation coefficient compared to laboratory tests, and continuous blood glucose monitoring modules are already commercially available. The miniaturization breakthroughs of these three types of devices make it possible to synchronously collect multiple parameters. In particular, the present invention can compress the complex analysis that traditionally requires a hospital laboratory into the computing power range of wearable devices. The essence of its technology lies in reconstructing the spatio-temporal dimension of medical monitoring - transforming discrete hospital tests into continuous home dynamic monitoring and shortening the warning response time from an average of several days to several hours.

[0016] According to a preferred embodiment, the detection unit can perform detection before the patient takes the medicine based on a preset frequency after the drug concentration in the patient's body reaches a steady state, so that the detection unit collects the above physiological parameters at the same time node, thereby ensuring that the blood drug concentration obtained by the detection unit is the steady-state trough concentration.

[0017] The present invention further optimizes the working mode of the detection unit to ensure that after the drug concentration in the patient's body reaches a steady state, detection is performed based on a preset frequency before the patient takes the medicine. This design ensures that the blood drug concentration collected each time is the steady-state trough concentration, thereby improving the accuracy and reliability of the data. After the drug is administered regularly multiple times, the intake amount and the metabolic excretion amount reach an equilibrium, and the concentration state at this time is called "steady state", which represents the most stable effect state of the drug in the body. By collecting the above physiological parameters at the same time node, not only the error caused by the drug concentration fluctuation is avoided, but also the consistency and comparability of the data are ensured. This is particularly important for long-term tracking of the patient's health trend, because only when all data points are obtained under the same conditions can the actual changes in the condition be truly reflected.

[0018] According to a preferred embodiment, the detection unit includes a first detection component for obtaining the blood drug concentration of the patient. The first detection component realizes the detection of the blood drug concentration based on LC-MS / MS technology. Among them, the first detection component includes: a sampling module for obtaining the fingertip blood of the patient; a pretreatment module for extracting the target drug from the sample; an analysis module with a built-in calibration curve and quality control samples; and an operation module for real-time data analysis.

[0019] The first detection component in the present invention adopts LC-MS / MS technology to realize the rapid detection of blood drug concentration, which not only significantly improves the detection speed and accuracy, but also reduces the operation difficulty. The sampling module uses a disposable blood sampling needle and a DBS sampling card to efficiently and painlessly obtain a trace amount of fingertip blood sample. The pretreatment module effectively extracts the target drug components through a portable centrifuge and a solid-phase extraction device, reduces matrix interference, and improves the detection sensitivity. The analysis module with a built-in calibration curve and quality control samples ensures the high accuracy and repeatability of the detection results, and the operation module supports Bluetooth or Wi-Fi connection, facilitating the real-time transmission of data to the processing unit. This highly integrated design not only simplifies the operation process, reduces human error, but also greatly shortens the detection time, enabling patients to complete the detection at home without having to go to the hospital frequently. This is of great significance for improving the treatment compliance and quality of life of patients, and at the same time provides timely and accurate data support for doctors to quickly adjust the treatment plan.

[0020] According to a preferred embodiment, the first detection component can add a liver enzyme activity detection channel in the analysis module to add the liver enzyme activity detection function. Among them, a liver enzyme activity sensor is configured in the liver enzyme activity detection channel to detect the activities of ALT and AST by electrochemical or optical methods.

[0021] The first detection component of the present invention adds a liver enzyme activity detection channel, which is equipped with a dedicated liver enzyme activity sensor and can detect the activities of ALT and AST through electrochemical or optical methods. This design enables the system to simultaneously obtain two key data, namely blood drug concentration and liver enzyme activity, during a single detection process, greatly facilitating the daily monitoring of patients. Liver enzyme activity directly reflects the state of liver metabolic function and is an important indicator for evaluating the metabolic rate of antiepileptic drugs. By real-time monitoring of liver enzyme activity, not only can changes in drug metabolic rate be detected in a timely manner, but also drug doses can be adjusted accordingly to avoid adverse reactions caused by too high or too low drug concentrations. In addition, the integrated detection channel design simplifies the operation steps, reduces the space occupied by the device, and improves the detection efficiency. For pregnant women with epilepsy who require long-term monitoring, this not only reduces the burden but also improves the accuracy of health management, helping to better maintain the drug efficacy and reduce side effects.

[0022] According to a preferred embodiment, the detection unit includes a second detection component for obtaining the blood glucose level of a patient, wherein the second detection component is configured as a portable blood glucose meter with a wireless transmission function, so that the second detection component can send the obtained blood glucose level data to the processing unit.

[0023] The detection unit of the present invention further includes a portable blood glucose meter with a wireless transmission function as the second detection component, which can conveniently obtain the blood glucose level data of the patient and transmit it to the processing unit wirelessly. Monitoring of blood glucose level is crucial for preventing epileptic seizures caused by hypoglycemia, especially during pregnancy when pregnant women have large blood glucose fluctuations and are prone to hypoglycemia. Traditional blood glucose monitoring methods usually require manual data recording, which is not only time-consuming and laborious but also prone to omissions or errors. The portable blood glucose meter equipped in the present invention, combined with the wireless transmission function, realizes the automatic collection and instant upload of blood glucose data, ensuring the integrity and timeliness of the data. This not only simplifies the daily operation of patients but also provides doctors with more comprehensive health information, facilitating timely adjustment of treatment plans and effectively reducing the risk of epileptic seizures. In addition, the wireless transmission function also improves the flexibility and convenience of the system, enabling patients to easily complete monitoring even when they are out, enhancing their self-management ability.

[0024] According to a preferred embodiment, the processing unit can substitute the physiological parameters obtained at the same time node into the corresponding functions for data processing, and then calculate the pregnancy epilepsy management index for characterizing the health trend of the patient by using a weighted method, wherein the processing unit can assign a corresponding time tag to the pregnancy epilepsy management index.

[0025] The processing unit of the present invention can substitute the physiological parameters obtained at the same time node into the corresponding functions for data processing respectively, calculate the Pregnancy Epilepsy Management Index (PEMI) by means of weighting, and assign corresponding time tags. This method not only takes into account the specific values of each physiological parameter, but also highlights the importance differences of different parameters through weighting processing. For example, the blood drug concentration directly affects the therapeutic effect and safety of drugs, so a higher weight should be assigned when calculating PEMI; although liver enzyme activity and blood glucose level are also important indicators, their weights can be adjusted appropriately according to specific circumstances. In this way, PEMI can more accurately reflect the overall health status of the patient and its potential risks. In addition, the practice of assigning time tags makes the PEMI data have a clear time sequence, which is convenient for subsequent trend analysis and dynamic monitoring. This feature is particularly crucial for identifying early health change trends, because it allows the system to predict the future health trend based on historical data, so as to take preventive measures in advance, effectively reduce the risk of epileptic seizures, and ensure the safety of the mother and baby.

[0026] According to a preferred embodiment, based on the time tags of the Pregnancy Epilepsy Management Index, the processing unit can generate a line graph of the change of the Pregnancy Epilepsy Management Index over time. Among them, a section of data in the stable period is selected as a reference to obtain the corresponding baseline PEMI value of this section of data, and the corresponding amplitude threshold reference value and slope threshold reference value are determined.

[0027] Based on the time tags of the Pregnancy Epilepsy Management Index, the processing unit of the present invention can generate a line graph of the change of PEMI over time, and select a section of data in the stable period as a reference to obtain the corresponding baseline PEMI value of this section of data. This method visually shows the change trend of PEMI through graphical display, enabling medical staff to intuitively observe the dynamic changes in the patient's health status. Selecting the data in the stable period as a reference ensures the accuracy and representativeness of the baseline PEMI value, providing a reliable benchmark for subsequent deviation analysis.

[0028] According to a preferred embodiment, the processing unit can judge the risk situation of the patient based on one or more of real-time comparison, short-term comparison, and stage comparison. Among them, real-time comparison means comparing the real-time line graph generated according to the calculated PEMI value with the set slope threshold; short-term comparison means comparing the fluctuation amplitudes of the peaks and valleys of multiple consecutive line graphs with the amplitude threshold reference value corresponding to the current pregnancy; stage comparison means comparing the area under the line of all line graphs in a complete pregnancy stage with the area under the line of the baseline PEMI value corresponding to the current pregnancy.

[0029] According to a preferred embodiment, whenever new data is added, the processing unit can adjust the slope threshold of the current broken line based on the slope threshold reference value corresponding to the pregnancy period and the parameters of the previous broken line. The set slope threshold includes a positive slope threshold and a negative slope threshold. Among them, the parameters of the previous broken line include its slope and the end PEMI value.

[0030] According to a preferred embodiment, the auxiliary system may include a display unit, which can receive the data information related to epilepsy during pregnancy transmitted by the processing unit and display it to the patient in a visual manner.

[0031] The auxiliary system of the present invention further includes a display unit, which can receive the data information related to epilepsy during pregnancy transmitted by the processing unit and display it to the patient in a visual manner. This design greatly enhances the patient's sense of participation and self-management ability. Through the clear and intuitive interface display, the patient can view their own health data at any time, understand the current treatment effect and potential risks. Especially for those patients who need long-term monitoring, this visual display not only simplifies the process of information understanding, but also enhances the patient's self-monitoring awareness and promotes the formation of good living habits. In addition, the display unit can also provide personalized health advice and warning information to help the patient better follow the doctor's advice and improve treatment compliance. This interactive health management method not only improves the patient's quality of life, but also provides more information about the patient's actual behavior and response to the doctor, which helps to formulate a more accurate and effective treatment plan. Brief Description of the Drawings

[0032] Figure 1 is the hardware connection diagram of the auxiliary system according to a preferred embodiment provided by the present invention;

[0033] Figure 2 is a schematic diagram of the broken line graph of the PEMI value generated by the processing unit according to a preferred embodiment provided by the present invention;

[0034] Figure 3 is a schematic diagram of the display panel of the display unit according to a preferred embodiment provided by the present invention.

[0035] List of Reference Numerals

[0036] 100: Detection unit; 110: First detection component; 111: Sampling module; 112: Pretreatment module; 113: Analysis module; 114: Operation module; 120: Second detection component; 121: Portable blood glucose meter; 200: Processing unit; 300: Display unit. Detailed Description of the Embodiment

[0037] The following is a detailed description with reference to the drawings.

[0038] Pregnancy complicated with epilepsy poses various challenges to the health of both the mother and the baby. It not only increases the health risks for the pregnant woman but also poses a potential threat to the normal development of the fetus. During pregnancy, due to factors such as hormonal fluctuations, changes in drug metabolism, and lack of sleep, the frequency of epileptic seizures may increase significantly. This not only affects the quality of life of the pregnant woman but also increases the risk of serious pregnancy complications such as miscarriage, premature birth, and placental abruption. In addition, the use of antiepileptic drugs (AEDs), although helpful in controlling epileptic seizures, may also cause a series of side effects in the mother, such as liver and kidney function damage, decreased bone density, and cognitive dysfunction. Especially at high doses, certain AEDs are more likely to trigger these adverse reactions. For the fetus, some antiepileptic drugs such as valproate sodium have been proven to be associated with an increased incidence of congenital diseases such as fetal neural tube defects, cardiovascular malformations, and cleft lip and palate. During a grand mal seizure, the mother may experience loss of consciousness or apnea, directly threatening the safety of the fetus, which may lead to intrauterine hypoxia and further affect its growth and development.

[0039] During pregnancy, a series of significant physiological changes occur in a woman's body, including changes in hormone levels, liver enzyme activity, and kidney function. These changes have an important impact on the metabolism of antiepileptic drugs: the increase in liver enzyme activity leads to faster drug metabolism, the increase in glomerular filtration rate reduces the retention time of drugs in the body, and the expansion of blood volume dilutes the drug concentration in the blood, further reducing the effectiveness of the drugs. Therefore, it is necessary to flexibly adjust the drug dose according to the results of blood drug concentration monitoring to ensure the therapeutic effect and reduce side effects.

[0040] Regular monitoring of the blood drug concentration of antiepileptic drugs is a key link in the management of pregnant women with epilepsy. Exemplarily, the following dynamic monitoring strategy can be adopted for collecting blood drug concentration: The first detection is in the early stage of pregnancy. When the drug dose is stable, it is recommended that the patient undergo a blood drug concentration test to determine the baseline level during pregnancy; in the second trimester (about 4 - 6 months), sampling and monitoring should be carried out once a month to ensure that the drug concentration remains within a safe and effective range; in the third trimester (about 7 - 9 months), as the embryo development enters a critical period and the drug metabolism speed accelerates, blood drug concentration should be detected every 2 - 4 weeks at this time to closely monitor the drug effect; if the frequency of epileptic seizures in the patient increases or drug-related side effects occur, a blood drug concentration test should be arranged immediately to adjust the treatment plan in a timely manner.

[0041] However, since epilepsy patients belong to the high-risk pregnancy population, relying solely on blood drug concentration detection once every few weeks or even once a month makes it difficult to comprehensively ensure the safety of pregnant women and fetuses. Traditional medical monitoring methods are difficult to meet the requirements of real-time and personalized needs. Especially when facing emergencies, they lack sufficient flexibility and response speed. In view of the above problems, the present invention discloses a self-management behavior assistance system for pregnant women with epilepsy to help patients better conduct self-management and monitoring, reduce risks caused by improper drug doses and other situations, thereby ensuring the safety of pregnant women and fetuses. In the present invention, the user of the assistance system is a pregnant woman with epilepsy (or simply referred to as the patient).

[0042] Preferably, as Figure 1 shown, the assistance system of the present invention may include: a detection unit 100 for obtaining the physiological parameters of the patient; a processing unit 200 for analyzing and processing the data obtained by the detection unit 100 to evaluate the health trend of the patient; and a display unit 300 for visually presenting data information related to pregnancy with epilepsy to the patient.

[0043] Preferably, the detection unit 100 may be a portable device or an intelligent sensor to obtain the physiological parameters of the patient related to pregnancy with epilepsy, wherein the physiological parameters related to pregnancy with epilepsy may include blood drug concentration, liver metabolism function (liver enzyme activity), and blood glucose level.

[0044] The blood drug concentration of antiepileptic drugs (AEDs) directly determines their therapeutic effect and safety. Especially during pregnancy, due to the increase in liver enzyme activity and glomerular filtration rate, drug metabolism accelerates, resulting in a possible significant decrease in blood drug concentration, which in turn affects the drug efficacy. Therefore, regular monitoring of blood drug concentration is crucial for ensuring the effectiveness and safety of drugs. Especially during pregnancy, as the internal environment changes, the drug dose needs to be dynamically adjusted to maintain a stable therapeutic effect. Preferably, the detection unit 100 of the present invention may be configured with a first detection component 110 for detecting the blood drug concentration of the patient, wherein the patient can use the first detection component 110 to collect the steady-state trough concentration. When the drug is administered regularly multiple times, the intake and metabolic excretion reach equilibrium, and the blood drug concentration no longer fluctuates significantly. The concentration state at this time is called "steady state". The steady state is generally reached after 4 to 5 times the half-life of the drug. Trough concentration: refers to the lowest concentration before the next dose, reflecting the lowest effective level of the drug in the body. Monitoring the trough concentration helps to evaluate whether the drug effect is stable enough to maintain epilepsy control. Therefore, the best blood sampling time for the patient to use the first detection component 110 is to collect blood before taking the drug when the concentration state reaches the steady state.

[0045] Preferably, the first detection component 110 of the present invention may include a sampling module 111, a pretreatment module 112, an analysis module 113, an operation module 114, and a power module. The sampling module 111 includes a disposable blood collection needle and a DBS sampling card, and is used to collect a small amount (10 - 50 μL) of fingertip blood. The DBS sampling card uses special filter paper to ensure uniform distribution and rapid drying of the blood. The pretreatment module 112 includes a portable centrifuge and a solid-phase extraction (SPE) device, and is used to extract the target drug from the DBS sample. The pretreatment module 112 is built-in with a standardized kit to simplify the operation process. The analysis module 113 uses a micro LC-MS / MS system, which integrates a chromatographic column and a mass spectrometer detector, and is used for quantitative analysis of the concentration of antiepileptic drugs. The analysis module 113 is built-in with a calibration curve and quality control samples to ensure the accuracy of the detection results. The operation module 114 includes an embedded processor and is used for real-time data analysis. The operation module 114 supports Bluetooth or Wi-Fi connection and can transmit data to the processing unit 200. The power module uses a rechargeable lithium battery to supply power to each module of the first detection component 110. Preferably, the first detection component 110 of the present invention can be used for rapid detection of various antiepileptic drugs, such as lamotrigine (LTG) and levetiracetam (LEV), etc., and among them, it is particularly suitable for detecting lamotrigine (LTG).

[0046] Preferably, the first detection component 110 of the present invention realizes rapid detection of blood drug concentration based on LC-MS / MS technology, and the specific principle is as follows: The patient uses a blood collection needle to collect fingertip blood and drops it onto the DBS sampling card. After the blood dries, the sampling card is inserted into the pretreatment module 112. The pretreatment module 112 removes matrix interference through centrifugation and solid-phase extraction to extract the target drug. The extracted sample enters the micro LC system and is separated by a C18 chromatographic column, and the mobile phase is methanol / water (containing 0.1% formic acid). The separated drug molecules enter the mass spectrometer detector, and the multiple reaction monitoring (MRM) mode is adopted to select characteristic ion pairs for quantitative analysis. The detection ion pairs of LTG and LEV are m / z256.1→210.1 and m / z 170.1→126.1 respectively. The operation module 114 can calculate the drug concentration according to the calibration curve. Further, the present invention can establish a calibration curve based on the linear regression model of standard samples. First, prepare a series of standard samples with known concentrations, and then use the LC-MS / MS system to perform quantitative analysis on them and record the signal intensity of each sample. Then, taking the signal intensity as the independent variable and the actual concentration of the standard sample as the dependent variable, a best straight line is fitted by the least squares method, that is, the required calibration curve is obtained. This curve can not only be used to calculate the concentration of unknown samples, but also ensure the high accuracy and repeatability of the detection results.

[0047] Exemplarily, the blood collection needle of the sampling module 111 adopts a disposable design to ensure aseptic operation. The DBS sampling card uses Whatman 903 filter paper, and the blood drying time is 15 - 30 minutes. The centrifuge speed of the pretreatment module 112 is 3000 rpm, and the centrifugation time is 5 minutes. The solid-phase extraction device uses a C18 column, and the eluent is methanol / water (70:30, v / v). The chromatographic column of the analysis module 113 is a C18 column (50 mm × 2.1 mm, 1.8 μm), and the mobile phase flow rate is 0.3 mL / min. The mass spectrometry detector uses an electrospray ionization (ESI) source in the positive ion mode. The embedded processor of the operation module 114 adopts the ARM Cortex-A53 architecture and runs the Linux operating system.

[0048] The first detection component 110 of the present invention has the following advantages: simple operation, users can complete sampling and detection without professional training; fast and accurate, the detection time is less than 30 minutes, and the results are accurate and reliable; highly portable, the detection component is small in size and light in weight; low cost, compared with traditional laboratory detection, the cost is reduced by more than 50%. In addition, the first detection component 110 of the present invention is suitable for home use because: First, the sampling module 111 adopts a micro blood sampling technique, only 10 - 50 μL of fingertip blood is required, and the sampling process is painless and safe, which is especially suitable for pregnant women with epilepsy to use at home. Second, the pretreatment module 112 and the analysis module 113 are highly integrated, and the operation process is simple. Users only need to follow the prompt steps to complete the detection without complex operations. In addition, the operation module 114 supports Bluetooth or Wi-Fi connection, and the detection results can be transmitted to the processing unit 200 in real time for subsequent analysis and processing. Finally, the portability and low cost of the detection component make it suitable for long-term home use. Patients can achieve real-time monitoring of blood drug concentration without frequent visits to medical institutions, thereby improving treatment compliance and efficacy.

[0049] Liver metabolic function, especially hepatic enzyme activity, directly affects the metabolic rate of anti-epileptic drugs. During pregnancy, hepatic enzyme activity is significantly enhanced, which may lead to accelerated drug metabolism and thus reduced blood drug concentration. Preferably, the present invention can realize the home detection of hepatic enzyme activity based on the dried blood spot (DBS) sampling technique and a portable biosensor. Among them, since the first detection component 110 of the present invention also uses the dried blood spot sampling technique, for hepatic enzyme activity, the present invention can choose to set up an independent detection component, or integrate the portable biosensor into the first detection component 110 to add the function of detecting hepatic enzyme activity.

[0050] Preferably, for the first detection component 110 with an additional liver enzyme activity detection function, the analysis module 113 can be configured in a multi-channel mode to increase the liver enzyme activity detection channels, so as to support the simultaneous analysis of blood drug concentration and liver enzyme activity. Among them, by switching the detection mode, the user can select single detection (blood drug concentration or liver enzyme activity) or combined detection. Preferably, in the liver enzyme activity detection channels, a liver enzyme activity sensor can be configured to detect the activities of ALT and AST by electrochemical or optical methods. Among them, the liver enzyme activity sensor can perform quantitative analysis by identifying the signals (such as current, light absorption) generated by enzyme-catalyzed reactions to calculate the liver enzyme activity. Exemplarily, the liver enzyme activity sensor adopts electrochemical sensing technology, and the detection time is 10 to 15 minutes.

[0051] Therefore, based on the user's detection needs, the first detection component 110 can output the blood drug concentration (unit: μg / mL) and / or the liver enzyme activity (unit: U / L). The first detection component 110 of the present invention can support the combined detection of blood drug concentration and liver enzyme activity, meeting various health monitoring needs.

[0052] Hypoglycemia is one of the important factors inducing epileptic seizures. Especially during pregnancy, the blood sugar of pregnant women fluctuates greatly and is prone to hypoglycemia. By regularly monitoring the blood sugar level, abnormalities can be detected in time and corresponding measures can be taken to avoid the risk of epileptic seizures. Hyperglycemia not only indicates the risk of gestational diabetes, but also may affect the normal development of the fetus, leading to problems such as premature birth and low birth weight. Therefore, stabilizing the blood sugar level is crucial for ensuring the health of the mother and baby. Preferably, the detection unit 100 of the present invention can be configured with a second detection component 120 for detecting the blood sugar level of the patient. Among them, the second detection component 120 can be configured as a portable blood glucose meter 121 and can have wireless transmission functions such as Bluetooth or Wi-Fi, so that the second detection component 120 can send the acquired blood sugar level data to the processing unit 200 for subsequent analysis and processing.

[0053] Preferably, the processing unit 200 can calculate the Pregnancy-Epilepsy Management Index (PEMI) based on the data information obtained by the detection unit 100. The calculation formula is as follows:

[0054] PEMI = w1·f(C blood ) + w2·g(E liver ) + w3·h(G blood ),

[0055] where C blood represents the blood drug concentration, E liver represents the liver enzyme activity, G bloodDenote the blood glucose level. w1, w2, and w3 are the weight coefficients of each factor respectively, reflecting their relative importance in the evaluation index (i.e., the pregnancy epilepsy management index), which can be set according to clinical experience and literature research. f(C blood ), g(E liver ), h(G blood ) are conversion functions for blood drug concentration, liver metabolism function, and blood glucose level respectively.

[0056] Preferably, the processing unit 200 can set the weight coefficients w1 (for blood drug concentration), w2 (for liver enzyme activity), and w3 (for blood glucose level) in stages according to the different characteristics of the first, second, and third trimesters of pregnancy. Further, in the first trimester of pregnancy, since the drug metabolism changes are relatively drastic and the importance of blood drug concentration is particularly prominent, the weight coefficients can be set as w1 = 0.60, w2 = 0.25, and w3 = 0.15 at this time. This setting emphasizes the key role of blood drug concentration in the initial management, helps to adjust the drug dose in a timely manner to maintain a stable therapeutic effect, and reduces the risks brought by drug concentration fluctuations. Entering the second trimester of pregnancy, as the fetal development accelerates and the liver metabolism function enhances, liver enzyme activity becomes one of the key monitoring points, and at the same time, the changes in blood glucose level also begin to be concerned. Therefore, at this stage, the weight coefficients can be adjusted to w1 = 0.45, w2 = 0.30, and w3 = 0.25. This adjustment not only reflects the importance of liver enzyme activity in evaluating the drug metabolism rate but also takes into account the impact of blood glucose fluctuations on the health of the mother and fetus, ensuring a comprehensive monitoring of the overall health status of the patient. In the third trimester of pregnancy, as the fetal volume increases and the maternal burden becomes heavier, the stability of blood glucose level is crucial for preventing epileptic seizures caused by hypoglycemia. At the same time, the blood drug concentration still needs to be strictly monitored to prevent insufficient active ingredients due to accelerated metabolism. Based on this, the weight coefficients at this stage can be adjusted to w1 = 0.40, w2 = 0.25, and w3 = 0.35. This setting highlights the role of blood glucose level in ensuring the safety of the mother and fetus, and at the same time takes into account the importance of the other two indicators, enabling the system to more accurately reflect the health trend of the patient. By flexibly adjusting the weight coefficients according to different pregnancy stages in this way, not only can it more accurately reflect the key points of patient health management in each period, but also effectively improve the accuracy and practicality of the PEMI calculation results. In addition, this method also supports further fine-tuning according to individual differences, enabling the system to better adapt to the unique needs of each patient, thereby providing more personalized medical services and support.

[0057] Preferably, for blood drug concentration, the method based on the standard score (Z-score) helps to standardize the concentration values of different drugs so that they can be compared on the same scale. Considering that both too low and too high blood drug concentrations may cause problems, a non-linear function can better reflect this bilateral risk.

[0058] Therefore, f(C blood ) can adopt the following function to reflect the change of blood drug concentration relative to the target value:

[0059]

[0060] where μ C is the midpoint of the target blood drug concentration or the treatment window, and σ C is the standard deviation of the blood drug concentration, representing the allowable range of concentration change.

[0061] This function will rapidly increase its influence when the blood drug concentration deviates from the target value, thus emphasizing the importance of maintaining within the treatment window.

[0062] Preferably, for liver enzyme activity, since the change in enzyme activity may be a monotonically increasing or decreasing relationship, using a logarithmic function can compress a large numerical range while maintaining sensitivity. In addition, if an increase in enzyme activity leads to accelerated drug metabolism, then the logarithmic function can also well reflect this proportional change. Therefore, g(E liver ) can adopt the following function to represent the change trend of liver metabolism function:

[0063]

[0064] where μ E is the reference enzyme activity level.

[0065] This function ensures that even if the enzyme activity is very high, its influence on the comprehensive score will not increase infinitely.

[0066] Preferably, for blood glucose level, considering that both hypoglycemia and hyperglycemia have potential hazards, a piecewise function can be used, or directly apply the minimum value function to limit the highest score to 1, so as to punish both too low and too high blood glucose levels, thereby preventing the influence of too high blood glucose from being overly amplified. Therefore, h(G blood ) can adopt the following function:

[0067]

[0068] where μ G is the ideal blood glucose level.

[0069] This function ensures that the score is the highest when the blood glucose level is within the ideal range, and the score will gradually decrease when it exceeds the ideal range.

[0070] Preferably, μ C , σ C , μ E , μ GAll can be set by medical staff based on clinical data, expert advice, and in combination with the individual differences of patients.

[0071] Preferably, the detection unit 100 of the present invention can perform a detection before taking medicine to ensure that the blood drug concentration is the steady-state trough concentration. Among them, the detection frequency can be once before each dose of medicine, or once before the next dose after taking medicine at intervals for multiple times. In other words, the detection frequency can be adjusted based on the advice of medical staff and / or the processing unit 200.

[0072] Preferably, the processing unit 200 can collect relevant data within each monitoring period, calculate the PEMI values based on these data, and connect these values into a broken line graph as shown in Figure 2 to intuitively reflect the change over time. Among them, the monitoring period can usually be divided based on the stage of pregnancy. For example, it can include the first trimester, the second trimester, and the third trimester of pregnancy, and can be further subdivided. Preferably, the processing unit 200 can pre-enter the baseline associated with the patient established in a medical institution at the beginning stage of different pregnancy periods. When establishing the baseline, a section of data during a stable period is selected as a reference, the corresponding baseline PEMI value (PEMI_base) of this section of data is obtained, and the corresponding amplitude threshold reference value and slope threshold reference value are determined.

[0073] Preferably, when the processing unit 200 determines the risk situation, it can adopt one or more of the following comparison methods: real-time comparison, short-term comparison, and stage comparison. Among them, real-time comparison means that the processing unit 200 can compare the real-time broken line generated according to the calculated PEMI value with the set slope threshold; short-term comparison means that the processing unit 200 can compare the fluctuation amplitudes of the peaks and troughs of multiple consecutive broken lines with the amplitude threshold reference value corresponding to the current pregnancy period; stage comparison means that the processing unit 200 can compare the area under the line of all broken lines in a complete pregnancy stage with the area under the line of the baseline PEMI value corresponding to the current pregnancy period.

[0074] Preferably, different gestational periods can correspond to different slope threshold reference values. When performing real-time comparison, the slope threshold of each broken line can be adjusted based on the slope threshold reference value corresponding to the gestational period and the parameters of the previous broken line, where the parameters of the previous broken line can include the slope and the end PEMI value (PEMI_end). Further, the set slope threshold can include a positive slope threshold and a negative slope threshold. Exemplarily, when the slope of the previous broken line is higher than its positive slope threshold and the end PEMI value is higher than the corresponding baseline PEMI value, the positive slope threshold and the negative slope threshold of the current broken line can be adjusted downward; when the slope of the previous broken line is lower than its negative slope threshold and the end PEMI value is lower than the corresponding baseline PEMI value, the positive slope threshold and the negative slope threshold of the current broken line can be adjusted upward. Whenever new data is added, the slope S_new of the latest broken line is recalculated, and it is determined whether it exceeds the threshold range adjusted by the above rules. According to the degree and direction of the exceedance, the system can provide different levels of feedback, such as "normal", "attention", "need to take action", to help the user make a quick response. In the process of improving real-time comparison, the present invention not only focuses on the immediate change trend of the PEMI value, but also introduces a prediction model based on historical data and individual differences of pregnant women to dynamically adjust the slope threshold of each broken line. This adjustment is not only based on different gestational periods to set a benchmark, but also refers to the specific parameters of the previous broken line such as the slope and the end PEMI value (PEMI_end), and is fine-tuned in combination with the physical condition of the current pregnant woman to ensure that the system can more accurately reflect the changes in the actual health status. At the same time, by setting positive and negative slope thresholds, the system can quickly respond when the PEMI value shows abnormal fluctuations, so as to timely warn of potential risks.

[0075] Exemplarily, when the system detects that the slope of the previous broken line exceeds the preset positive slope threshold and the end PEMI value is higher than the baseline PEMI value, it indicates that there may be potential risks in the current health status. At this time, the system automatically reduces the current positive slope threshold by 10%. For example, if the original positive slope threshold is 0.8, the adjusted slope is 0.72, and the negative slope threshold can also be adjusted downward accordingly. Such an adjustment aims to adapt to the changes in the physical condition of the pregnant woman and more sensitively capture the signs of deterioration of the health trend. On the contrary, if the slope of the previous broken line is lower than the negative slope threshold and the end PEMI value is lower than the baseline PEMI value, in this case, the system will increase the current negative slope threshold by 10% to reduce the possibility of false alarms and ensure the accuracy of the early warning system, and the positive slope threshold can also be adjusted upward accordingly.

[0076] For short-term comparison, based on comparing the peak and trough fluctuation amplitudes of consecutive polyline graphs, the periodicity and regularity of the waveforms can be further analyzed, and combined with the pregnant woman's living habits, such as sleep quality and diet, etc., to provide a reasonable explanation for these fluctuations. This method can not only identify abnormal fluctuations in PEMI values in the short term, but also further explore the reasons behind these fluctuations, so as to formulate more effective intervention measures. In addition, by comparing the fluctuation amplitude with the amplitude threshold reference value corresponding to the current pregnancy period, the risk level in the short term can be better evaluated, providing a basis for early intervention.

[0077] During stage comparison, a standard PEMI offline area database for each pregnancy period can be established and updated regularly to reflect different individual differences and physiological changes during pregnancy progression. This method not only considers numerical changes, but also pays attention to the trend changes of PEMI values throughout the pregnancy period, ensuring the stability and safety of long-term treatment effects. By comparing the offline area of all polyline graphs in a complete pregnancy stage with the offline area of the baseline PEMI value corresponding to this pregnancy period, a comprehensive evaluation of the effectiveness of the treatment plan can be provided for doctors, so as to adjust the drug dosage or other treatment strategies in a timely manner.

[0078] Exemplarily, for a patient in the second trimester of pregnancy, the weight coefficients in the processing unit 200 can be set as: w1 = 0.45 (blood drug concentration), w2 = 0.30 (liver enzyme activity), and w3 = 0.25 (blood glucose level), and based on the standard score method, the target blood drug concentration μC can also be set to 15 μg / mL, the standard deviation σC to 3; the reference enzyme activity μE to 40 U / L; the ideal blood glucose level μG to 95 mg / dL. The baseline PEMI value of this patient is 60, the positive slope threshold is set to 0.8, and the negative slope threshold is set to -0.8. During a regular monitoring, the following physiological parameters were obtained: blood drug concentration (C blood ) is 12 μg / mL, liver enzyme activity (E liver ) is 45 U / L, blood glucose level (G blood) is 90 mg / dL. The processing unit 200 can substitute into the formula to calculate that the PEMI value is approximately 57.3. Further, the slope of the previous section of the broken line is 0.75, and the PEMI value at the end is 60. The newly calculated PEMI value is significantly lower than the baseline PEMI value, indicating that there may be a health risk. The system recalculates the slope S_new of the latest section of the broken line and finds that it is lower than the negative threshold of the slope -0.8, then automatically increases the positive and negative thresholds of the current slope by 10%. However, the new PEMI value is still significantly lower than the baseline PEMI value. Therefore, the system sends a feedback message of "Attention", suggesting further observation or taking measures. For example, it may be necessary to adjust the drug dosage or increase the monitoring frequency to ensure the safety of the pregnant woman and the fetus. Through this dynamic adjustment mechanism, not only can the actual health status change of the pregnant woman be more accurately reflected, but also potential risks can be timely warned, making medical intervention more timely and effective. In addition, the personalized adjustment based on real-time data also enhances the flexibility and response speed of the system, helps medical staff and patients make quick and accurate decisions, thereby improving the monitoring accuracy and ensuring the safety of the mother and baby.

[0079] Preferably, as Figure 3 shown, the processing unit 200 can send the generated broken line graph and the evaluation result to the display unit 300. Through the visualization display function of the display unit 300, it displays contents such as the PEMI broken line, the reference slope, the current slope, the threshold value after dynamic adjustment, and the baseline PEMI value, enabling the user to intuitively understand the current situation. At the same time, the intelligent reminder mechanism will automatically send warning messages of different levels according to the deviation analysis result, improving the decision-making efficiency of the user.

[0080] To ensure the continuous optimization of the system, the present invention also designs an adaptive learning mechanism, allowing the system to continuously adjust the parameter settings according to historical data to improve the prediction accuracy. By regularly evaluating the system performance, including the effectiveness and accuracy of the threshold adjustment, and timely adjusting the parameter settings (such as the scaling factor, etc.) according to the feedback in the actual application, the technical solution of the present invention can better meet the monitoring and evaluation requirements.

[0081] It should be noted that the above specific embodiments are exemplary. Those skilled in the art can come up with various solutions inspired by the disclosure of the present invention, and these solutions also fall within the scope of the disclosure of the present invention and within the protection scope of the present invention. Those skilled in the art should understand that the description and drawings of the present invention are illustrative and do not constitute a limitation to the claims. The protection scope of the present invention is defined by the claims and their equivalents. The description of the present invention contains multiple inventive concepts. Expressions such as "preferably" or "according to a preferred embodiment" indicate that the corresponding paragraphs disclose an independent concept. The applicant reserves the right to file divisional applications based on each inventive concept. Throughout the text, the features guided by "preferably" are only optional ways and should not be understood as being necessarily provided. Therefore, the applicant reserves the right to waive or delete the relevant preferred features at any time.

Claims

1. A self - management behavior assistance system for pregnant women with epilepsy, characterized in that, It includes: A detection unit (100) for obtaining physiological parameters of a patient related to pregnancy complicated with epilepsy; A processing unit (200) for analyzing and processing the data obtained by the detection unit (100) to evaluate the health trend of the patient, wherein The physiological parameters obtained by the detection unit (100) include blood drug concentration, liver enzyme activity, and blood glucose level, so that the processing unit (200) can calculate a pregnancy epilepsy management index for characterizing the health trend of the patient based on the above physiological parameters to judge the epilepsy risk of the patient during the current pregnancy.

2. The auxiliary system according to claim 1, characterized in that, After the drug concentration in the patient's body reaches a steady state, the detection unit (100) can perform detection before the patient takes the medicine based on a preset frequency, so that the detection unit (100) collects the above physiological parameters at the same time node, thereby ensuring that the blood drug concentration obtained by the detection unit (100) is the steady-state trough concentration.

3. The auxiliary system according to claim 1 or 2, characterized in that, The detection unit (100) includes a first detection component (110) for obtaining the blood drug concentration of the patient. The first detection component (110) realizes the detection of the blood drug concentration based on LC-MS / MS technology. Among them, the first detection component (110) includes: A sampling module (111) for obtaining the fingertip blood of the patient; A pretreatment module (112) for extracting the target drug from the sample; An analysis module (113) with a built-in calibration curve and quality control samples; An operation module (114) for real-time data analysis.

4. The auxiliary system according to any one of claims 1 to 3, characterized in that The first detection component (110) can add a liver enzyme activity detection channel in the analysis module (113) to add the liver enzyme activity detection function. Among them, a liver enzyme activity sensor is configured in the liver enzyme activity detection channel to detect the activities of ALT and AST by electrochemical or optical methods.

5. The auxiliary system according to any one of claims 1 to 4, characterized in that, The detection unit (100) includes a second detection component (120) for obtaining the blood glucose level of the patient. Among them, the second detection component (120) is configured as a portable blood glucose meter (121) with a wireless transmission function, so that the second detection component (120) can send the obtained blood glucose level data to the processing unit (200).

6. The auxiliary system according to any one of claims 1 to 5, characterized in that, The processing unit (200) can substitute the physiological parameters obtained at the same time node into the corresponding functions for data processing, and then calculate the pregnancy epilepsy management index for characterizing the health trend of the patient by means of weighting. Among them, the processing unit (200) can assign corresponding time tags to the pregnancy epilepsy management index.

7. The auxiliary system according to any one of claims 1 to 6, characterized in that Based on the time tag of the pregnancy epilepsy management index, the processing unit (200) can generate a line chart of the change of the pregnancy epilepsy management index over time. Among them, a section of stable period data is selected as a reference to obtain the corresponding baseline PEMI value of this section of data, and the corresponding amplitude threshold reference value and slope threshold reference value are determined.

8. The auxiliary system according to any one of claims 1 to 7, characterized in that, The processing unit (200) can determine the risk situation of the patient based on one or more of real-time comparison, short-term comparison, and stage comparison. Among them, real-time comparison means comparing the real-time broken line generated according to the calculated PEMI value with the set slope threshold; short-term comparison means comparing the fluctuation amplitudes of the peaks and valleys of multiple consecutive broken lines with the amplitude threshold reference value corresponding to the current pregnancy; stage comparison means comparing the area under the line of all broken lines in a complete pregnancy stage with the area under the line of the baseline PEMI value corresponding to the current pregnancy.

9. The auxiliary system according to any one of claims 1 to 8, characterized in that, Whenever new data is added, the processing unit (200) can adjust the slope threshold of the current broken line based on the slope threshold reference value corresponding to the pregnancy and the parameters of the previous broken line. The set slope threshold includes a positive slope threshold and a negative slope threshold. Among them, the parameters of the previous broken line include its slope and the end PEMI value.

10. The auxiliary system according to any one of claims 1 to 9, characterized in that, It includes a display unit (300), and the display unit (300) can receive the data information related to pregnancy complicated with epilepsy transmitted by the processing unit (200) and display it to the patient in a visual way.

Citation Information

Cited By

  • Application method and system of intervention model for predicting health of pregnant woman with epilepsy

    CN122417432A

  • Method and system for selecting a suitable model for predicting offspring health of a pregnant woman with epilepsy

    CN122511610A